Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder characterized by intravascular hemolysis and thrombosis. The most serious complication is thrombosis, the risk of which is augmented by the hyper-coagulable state that occurs during pregnancy; despite this risk, however, you...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2013-04, Vol.97 (4), p.491-497
Main Authors: Morita, Yasuyoshi, Nishimura, Jun-ichi, Shimada, Takahiro, Tanaka, Hirokazu, Serizawa, Kentaro, Taniguchi, Yasuhiro, Tsuritani, Mitsuhiro, Kanakura, Yuzuru, Matsumura, Itaru
Format: Article
Language:English
Subjects:
Adult
Anemias. Hemoglobinopathies
Antibodies, Monoclonal, Humanized - therapeutic use
Anticoagulants - therapeutic use
Biological and medical sciences
Case Report
Diseases of red blood cells
Female
Hematologic and hematopoietic diseases
Hematology
Hemoglobinuria, Paroxysmal - diagnosis
Hemoglobinuria, Paroxysmal - drug therapy
Heparin, Low-Molecular-Weight - analogs & derivatives
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Medical sciences
Medicine
Medicine & Public Health
Oncology
Pregnancy
Pregnancy Outcome
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder characterized by intravascular hemolysis and thrombosis. The most serious complication is thrombosis, the risk of which is augmented by the hyper-coagulable state that occurs during pregnancy; despite this risk, however, young female PNH patients often desire to have a baby. We recently experienced two successful deliveries in PNH patients, who were treated with anticoagulant therapy during their pregnancies. Meanwhile, given the potential benefit of eculizumab (Soliris), a humanized monoclonal antibody against C5, in reducing thrombosis and hemolysis, it represents a promising therapeutic option for the treatment of pregnant PNH patients in combination with, or in replacement of, anticoagulant therapy.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-013-1302-3